• Home
  • /
  • Topic
  • /
  • Government
  • /
  • Fda
  • /
  • Why the FDA Should Prohibit the Direct Advertising of Prescription Drugs to the Consumer Term Paper
Verified Document

Why The FDA Should Prohibit The Direct Advertising Of Prescription Drugs To The Consumer Term Paper

Limiting DTC drug ads

The moratorium on direct-to-consumer (DTC) prescription drug ads protected patients because it enabled health care practitioners and other professionals to make educated, informed decisions about potentially harmful substances rather than the consumer relying on materials designed exclusively at sales, promotion, and marketing.

DTC drug ads should be again limited by the FDA because the advertisements are potentially misleading, causing consumers to request drugs that they have seen on television or in print ads. These ads can offer what are essentially "miracle" cures, while downplaying potential harmful side effects or by failing to mention other alternatives. "Most direct-to-consumer advertising does not warn patients of drug-drug interactions," ("Direct to Consumer Advertising"). Moreover, many patients might stop taking the medication they are currently on because they see an ad for something else.

The FDA should be dedicated to promoting public health and safety. If prescription drug advertisements interfere at all with this primary objective then the DTC approach to the pharmaceutical industry must be more carefully examined and reconsidered.

DTC prescription drug ads interfere with spending that could be channeled into research and development of new products; an exorbitant amount of money is spent on drug advertisements.

The drugs that are promoted in DTC ads become best-sellers (Collins et al.). Therefore, the DTC ads create an unfair and unbalanced marketplace.

While the FDA should permit the dissemination of information by pharmaceutical companies to consumers, that information must be presented in fair and balanced ways. Patients do have the right to make informed, independent decisions related to their choice of health care plan, but these choices must not be made based on marketing and money-making but rather, on optimal health.

Works Cited

Collins, Susan, et. al. "Prescription Drugs: FDA Oversight of Direct-to-Consumer Advertising Has Limitations." United States General Accounting Office. Oct 2002. .

'Direct to Consumer Advertising for Prescription Drugs." American College of Physicians. 9 Oct 1998. .

'Prescription Drugs and Mass Media Advertising." National Institute for Health Care Management Research and Educational Foundation. Nov. 2001. .

Cite this Document:
Copy Bibliography Citation

Related Documents

FDA: Center for Drug Evaluation and Research
Words: 1105 Length: 3 Document Type: Essay

FDA: Center for Drug Evaluation and Research (CDER) And Over-the-counter Weight Loss Medications Obesity is one of the most serious epidemics facing the American public. "Over two-thirds of adults in the United States are overweight or obese, and over one-third are obese" (Overweight and obesity statistics, 2012, WIN). To address concerns about obesity, many adults turn to over-the-counter medications like dietary supplements that promise the user easy weight loss. The medications usually

FDA Classification the FDA Is
Words: 577 Length: 2 Document Type: Term Paper

Given that there is no expectation of substantial equivalence, the following process will need to be undertaken. The 510(K) that needs to be submitted is the Traditional. A Special is for modifications to products that already have 510(k) approval, so that does not apply in this case. An Abbreviated 510(K) applies when a product is approved for this process by the FDA. There is little explanation on the FDA website

FDA Health Policy on Intravesical
Words: 3065 Length: 10 Document Type: Research Paper

Phase II consists of efficacy trials of the drug, which are tested on volunteers of the target population. When everything goes right, the drug manufacturer discusses the development process, continued human testing, other concerns and protocols for phase III with the FDA. Phase III is the more extensive. It is at this time that the manufacture can work for the accelerated development and review of the drug. Treatment IND

FDA and Gene Therapy
Words: 892 Length: 2 Document Type: Term Paper

Gene Therapy FDA Ethics can be considered to come from personal values. From both a medical and a business perspective, ethics are the reasons that some news stories should be followed from beginning to end and all in between. "On Sunday morning, 23 February 1997, the world awoke to a technological advance that shook the foundations of biology and philosophy. On that day, we were introduced to Dolly, a 6-month-old lamb that

FDA Homeopathics
Words: 748 Length: 2 Document Type: Essay

Divisions of the FDA The FDA is in charge of the regulation of pharmaceutical drugs and medical devices, as part of its mandate to safeguard the U.S. health care system. One unit for this is the Center for Devices and Radiological Health (CDRH), which approves medical devices. The unit that approves drugs is the Center for Drug Evaluation and Research (CDER). There is also the Center for Biologics Evaluation and Research

FDA and Its Regulatory Powers
Words: 1619 Length: 4 Document Type: Essay

Administrative Law REGULATING STEM CELL THERAPY Administrative Agency: Food and Drug Administration Article 1 Section 1 of the federal Constitution creates administrative agencies, which are law-making entities but with limited powers (USLegal, 2014). The rules and regulations created by an administrative agency are lawfully enforceable. It assists in the faster management of cases and is, therefore, a big help to U.S. courts. The administrative process is also a valuable resource for other important

Sign Up for Unlimited Study Help

Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.

Get Started Now